The metabolic fate of [14C]-fenclozic acid in the hepatic reductase null (HRN) mouse

Xenobiotica

Volumn 44, Issue 2, 2014, Pages 164-173

  Pickup, Kathryn ^a   Wills, Jonathan ^a   Rodrigues, Alison ^b   Jones, Huw B ^a   Page, Chris ^c   Martin, Scott ^a   Sarda, Sunil ^a   Wilson, Ian ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Argenta Discovery Ltd   (United Kingdom)

Author keywords

Drug metabolism; Fenclozic acid; HRN mouse

Indexed keywords

CARBON 14; DRUG METABOLITE; FENCLOZIC ACID; LIVER ENZYME; OXIDOREDUCTASE; CARBON; GLYCINE; TAURINE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; FECES ANALYSIS; HISTOPATHOLOGY; ISOTOPE LABELING; KIDNEY CORTEX; KIDNEY MEDULLA; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; LIVER; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RHEUMATOID ARTHRITIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY EXCRETION; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; AUTORADIOGRAPHY; CHEMISTRY; DRUG DETOXIFICATION; DRUG EFFECT; FECES; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION; URINE;

ANIMALS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; FECES; GLYCINE; LIVER; MALE; METABOLIC DETOXICATION, DRUG; MICE; MICE, KNOCKOUT; OXIDOREDUCTASES; TAURINE; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84893133798     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.866299     Document Type: Article

References (17)

1. Alcock S. (1971). An anti-inflammatory compound: non-toxic to animals but with an adverse action in man. Proc Eur Soc Study Drug Toxic 12:184-90.
2. Boelsterli UA. (2002). Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab 3:439-50.
3. Bradbury A, Powell GM, Curtis CG, Rhodes C. (1981). The enhanced biliary secretion of a taurine conjugate in the rat after intraduodenal administration of high doses of fenclozic acid. Xenobiotica 11: 665-74.
4. Chalmers TM, Kellgren JH, Platt DS. (1969a). Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflamatory agent. II. Clinical trial in patients with rheumatoid arthritis. Ann Rheum Dis 28:595-601.
5. Chalmers TM, Pohl JE, Platt DS. (1969b). Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflammatory agent. I. Serum concentration studies in healthy individuals and in patients with rheumatoid arthritis. Ann Rheum Dis 28:590-4.
6. FDA. (2008). FDA Guidance for Industry: Safety Testing of Drug Metabolites. FDA Guidance on safety testing of drug metabolites. (2008). Retrieved from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf [last accessed 2 Dec 2013].
7. Foulkes DM. (1970). The metabolism of C14-ICI 54,450 (myalex) in various species - an in vivo NIH shift. J Pharmacol Exp Ther 172: 115-21.
8. Hart FD, Bain LS, Huskisson EC, et al. (1970). Hepatic effects of fenzlozic acid. Ann Rheum Dis 29:684.
9. Knights KM, Sykes MJ, Miners JO. (2007). Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opin Drug Metab Toxicol 3:159-68.
10. Le Y, Sauer B. (2001). Conditional gene knockout using Cre recombinase. Mol Biotechnol 17:269-75.
11. Newbould BB. (1969). The pharmacology of fenclozic acid (2-(4- chlorophenyl)-thiazol-4-ylacetic acid; I.C.I. 54,450; 'Myalex'); a new compound with anti-inflammatory, analgesic and antipyretic activityl. Br J Pharmacol 35:487-97.
12. Pickup K, Gavin A, Jones HB, et al. (2012). The hepatic reductase null mouse as a model for exploring hepatic conjugation of xenobiotics: application to the metabolism of diclofenac. Xenobiotica 42: 195-205.
13. Rodrigues AVM, Rollison HE, Martin S, et al. (2013). In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. Arch Toxicol 87:1569-79.
14. Skonberg C, Olsen J, Madsen KG, et al. (2008). Metabolic activation of carboxylic acids. Expert Opin Drug Metab Toxicol 4:425-38.
15. Stachulski AV, Harding JR, Lindon JC, et al. (2006). Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis. J Med Chem 49:6931-45.
16. Thompson RA, Isin EM, Li Y, et al. (2012). In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Tox 25:1616-32.
17. Ullberg S. (1954). Studies on the distribution and fate of [35S]-labelled benzylpenicillin in the body. Acta Radiol Suppl 118:1-110.